Tumour lysis syndrome in solid tumours.
Tumour lysis syndrome (TLS) is an oncological emergency that results from massive cytolysis of malignant cells with a sudden release of their cellular contents, such as intracellular ions and metabolic by-products, into the systemic circulation. This syndrome is common in tumours with rapid cell turnover and growth rates, and in bulky tumours with high sensitivity to antineoplastic treatments. It is, therefore, a well-recognised clinical problem in haematological malignancies. It is rarely observed in solid tumours. Here, published studies are reviewed, beginning with the first report of TLS in solid tumours. Reported solid TLS cases are evaluated according to their common features and differences, and their similarities with those seen in haematological malignancies. Basic principles for the prevention and management of TLS are mentioned, with particular emphasis on solid tumours.
Gemici
C
C
Dr Lutfi Kirdar Kartal Education and Research Hospital, Department of Oncology, Istanbul, Turkey. cegemici@yahoo.com
D049109:Cell Proliferation; D005260:Female; D019337:Hematologic Neoplasms / Q000150:complications* / Q000175:diagnosis; D006801:Humans; D033461:Hyperuricemia / Q000175:diagnosis; D006996:Hypocalcemia / Q000175:diagnosis; D007477:Ions; D008297:Male; D009369:Neoplasms / Q000150:complications* / Q000175:diagnosis; D011379:Prognosis; D051437:Renal Insufficiency; D012307:Risk Factors; D015275:Tumor Lysis Syndrome / Q000175:diagnosis* / Q000473:pathology* / Q000628:therapy
D007477:Ions